Pharmaceutical

Risk adjusted net present value: What is the current valuation of Forte Biosciences’s FB-102?

FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Celiac Disease.

Dec 15, 2024 - 06:00
FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Celiac Disease.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of CRISPR Therape...

Next Article

Risk adjusted net present value: What is the current valuation of Tenaya Therape...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Emergent to sell US sterile manufacturing facility to Bora

Emergent to sell US sterile manufacturing facility to Bora

Jun 22, 2024

China’s NMPA approves Henlius’ oesophageal cancer therapy

China’s NMPA approves Henlius’ oesophageal cancer therapy

Sep 25, 2023

STAT+: Pharmalittle: FDA approvals will stop if U.S. defaults on its debts; DEA failed to punish wholesaler blamed in opioid crisis

STAT+: Pharmalittle: FDA approvals will stop if U.S. de...

May 25, 2023